Filenews 24 May 2021
Under investigation by the EMA is the thromboembolic episode that resulted in the death of the 39-year-old, who a few days earlier received an AstraZeneca vaccine. Under the microscope of the European Medicines Agency are other thromboembolic episodes that have occurred in vaccinated people with this preparation.
The European Medicines Agency, in its announcements, reports that cases of abnormal blood clots with low platelets have occurred in people treated with Vaxzevria (formerly COVID-19 Vaccine AstraZeneca).
What the public needs to know
According to an EMA announcement, those who have had blood clots with low platelets should not receive the second dose of AstraZeneca after receiving the first dose of the vaccine.
At the same time, it calls on citizens to seek immediate medical assistance if they have experienced any of the following symptoms within three weeks of vaccination:
▪ shortness of breath
▪ chest pain
▪ swelling in the legs
▪ pain in the legs
▪ persistent abdominal pain
▪ neurological symptoms such as severe and persistent headaches, blurred vision, confusion or seizures (crises)
▪ unusual skin bruises or finding round spots beyond the injection site.
Information for health professionals
The EMA introduces a contraindication for Vaxzevria (COVID-19 AstraZeneca vaccine) in people who have had thrombosis with thrombocytopenia syndrome (TTS) after prior administration of this vaccine.
• As TTS requires specialized treatment, health professionals should consult current guidance and/or specialists (e.g. a matologist and a coagulation specialist) to diagnose and treat the condition.
• Health professionals should check for signs of thrombosis in any person who has thrombocytopenia within 3 weeks of vaccination with Vaxzevria. Similarly, they should check for signs of thrombocytopenia in any person who has thrombosis within 3 weeks of vaccination.
• Health professionals should continue to advise people to seek urgent medical help if they have symptoms indicating thrombosis or thrombocytopenia.
Health professionals will receive a direct contact of a healthcare professional (DHPC) with the above information. THE DHPC will also be available on a dedicated page on the EMA website.
